Luye Pharma Group Ltd - Asset Resilience Ratio
Luye Pharma Group Ltd (LUP) has an Asset Resilience Ratio of 9.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Luye Pharma Group Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Luye Pharma Group Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see LUP total asset value.
Liquid Assets Composition Over Time
This chart breaks down Luye Pharma Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Luye Pharma Group Ltd total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.00 Billion | 9.15% |
| Total Liquid Assets | €3.00 Billion | 9.15% |
Asset Resilience Insights
- Limited Liquidity: Luye Pharma Group Ltd maintains only 9.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Luye Pharma Group Ltd Industry Peers by Asset Resilience Ratio
Compare Luye Pharma Group Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Luye Pharma Group Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Luye Pharma Group Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.15% | €3.00 Billion ≈ $3.51 Billion |
€32.83 Billion ≈ $38.38 Billion |
+3.86pp |
| 2024-12-31 | 5.29% | €1.57 Billion ≈ $1.83 Billion |
€29.61 Billion ≈ $34.62 Billion |
-5.96pp |
| 2023-12-31 | 11.25% | €2.87 Billion ≈ $3.35 Billion |
€25.49 Billion ≈ $29.80 Billion |
-2.03pp |
| 2022-12-31 | 13.28% | €3.22 Billion ≈ $3.77 Billion |
€24.25 Billion ≈ $28.35 Billion |
-0.32pp |
| 2021-12-31 | 13.60% | €3.07 Billion ≈ $3.59 Billion |
€22.58 Billion ≈ $26.40 Billion |
+6.13pp |
| 2020-12-31 | 7.47% | €1.54 Billion ≈ $1.80 Billion |
€20.63 Billion ≈ $24.12 Billion |
-7.35pp |
| 2019-12-31 | 14.82% | €2.86 Billion ≈ $3.35 Billion |
€19.31 Billion ≈ $22.58 Billion |
-3.36pp |
| 2018-12-31 | 18.19% | €3.19 Billion ≈ $3.73 Billion |
€17.54 Billion ≈ $20.50 Billion |
-5.75pp |
| 2017-12-31 | 23.93% | €2.58 Billion ≈ $3.01 Billion |
€10.76 Billion ≈ $12.58 Billion |
-1.59pp |
| 2016-12-31 | 25.52% | €2.35 Billion ≈ $2.75 Billion |
€9.21 Billion ≈ $10.76 Billion |
-- |
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more